Spots Global Cancer Trial Database for Study of PYX-106 in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of PYX-106 in Solid Tumors
Official Title: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
Study ID: NCT05718557
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
University of California San Diego, La Jolla, California, United States
University of Southern California, Los Angeles, California, United States
SCRI- HealthOne Denver, Denver, Colorado, United States
University of Chicago Medicine, Chicago, Illinois, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Gabrail Cancer and Research Center, Canton, Ohio, United States
NEXT Oncology, Irving, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Grand Hôpital de Charleroi - Notre Dame, Charleroi, Hainaut, Belgium
Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium
Cliniques Universitaires Saint-Luc, Brussels, , Belgium
Hospital Universitari Dexeus, Barcelona, , Spain
START Madrid - Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
HM Centro Integral Oncológico Clara Campal, Madrid, , Spain
Hospital Clínico Universitario de Valencia, Valencia, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
